Shima Aboutalebian

Shima Aboutalebian

Auto-generated profile, based on publicly available information

Shima Aboutalebian

Department of Medical Parasitology and Mycology, School of Medicine Isfahan University of Medical Sciences Isfahan Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in Mycoses
Verified
Journal Article
Closed access
PDF file
HMHossein Mirhendi
Hossein Mirhendi
ACArezou Charsizadeh
Arezou Charsizadeh
SAShima Aboutalebian
Shima Aboutalebian
MMMasoud Mohammadpour
Masoud Mohammadpour
BNBahram Nikmanesh
Bahram Nikmanesh
Hamid BadaliHamid Badali
Hamid Badali

2 March 2023 in Medical Mycology
Verified
Journal Article
Closed access
PDF file
MEMahzad Erami
Mahzad Erami
SAShima Aboutalebian
Shima Aboutalebian
SHSeyed Jamal Hashemi Hezaveh
Seyed Jamal Hashemi Hezaveh
RGRoshanak Daie Ghazvini
Roshanak Daie Ghazvini
MMMansooreh Momen-Heravi
Mansooreh Momen-Heravi
HMHossein Mirhendi
Hossein Mirhendi
Since global COVID‐19 spread worldwide, invasive fungal rhinosinusitis (IFRS) emerged in immunocompromised patients as a new clinical challenge. In this study, clinical specimens of eighty-nine COVID-19 patients who presented clinical and radiological evidence suggestive of IFRS, were examined by direct microscopy, histopathology, and culture, and the isolated colonies were identified through DNA sequence analysis. Fungal elements were microscopically observed in 84.27% of the patients. Males (53.9%) and patients over 40 (95.5%) were more commonly affected than others. Headache (94.4%) and retro-orbital pain (87.6%) were the most common symptoms, followed by ptosis/proptosis/eyelid swelling (52.8%), and 74 patients underwent surgery and debridement. The most common predisposing factors were steroid therapy (n = 83, 93.3%), diabetes mellitus (n = 63, 70.8%), and hypertension (n = 42, 47.2%). The culture was positive for 60.67% of the confirmed cases, and Mucorales were the most prevalent (48.14%) causative fungal agents. Different species of Aspergillus (29.63%) and Fusarium (3.7%) and a mix of two filamentous fungi (16.67%) were other causative agents. For 21 patients, no growth was seen in culture despite a positive result on microscopic examinations. In PCR-sequencing of 53 isolates, divergent fungal taxons including eight genera and 17 species, were identified as followed: Rhizopus oryzae (n = 22), Aspergillus flavus (n = 10), Aspergillus fumigatus (n = 4), Aspergillus niger (n = 3), Rhizopus microsporus (n = 2), Mucor circinelloides, Lichtheimia ramosa, Apophysomyces variabilis, Aspergillus tubingensis, Aspergillus alliaceus, Aspergillus nidulans, Aspergillus calidoustus, Fusarium fujikuroi/proliferatum, Fusarium oxysporum, Fusarium solani, Lomentospora prolificans and Candida albicans (each n = 1). In conclusion, a diverse set of species involved in COVID-19-associated IFRS was observed in this study. Our data encourage specialist physicians to consider the possibility of involving various species in IFRS in immunocompromised and COVID-19 patients. In light of utilizing molecular identification approaches, the current knowledge of microbial epidemiology of invasive fungal infections, especially IFRS, may change dramatically. Invasive fungal rhinosinusitis (IFRS) may infect people with diabetes, cancer, or COVID-19. In this study, various types of fungi were identified from COVID-19-associated-IFRS, encouraging physicians to consider specific treatments.

31 December 2024 in Mycoses
Verified
Journal Article
Closed access
HMHossein Mirhendi
Hossein Mirhendi
SAShima Aboutalebian
Shima Aboutalebian
ZJZahra Jahanshiri
Zahra Jahanshiri
FRFaezeh Rouhi
Faezeh Rouhi
MSMohammad‐Reza Shidfar
Mohammad‐Reza Shidfar
MRMahnaz Hosseini Rizi
Mahnaz Hosseini Rizi

2 January 2025 in Mycoses
Verified
Journal Article
Closed access
FRFaezeh Rouhi
Faezeh Rouhi
SAShima Aboutalebian
Shima Aboutalebian
ARAli Rezaei-Matehkolaei
Ali Rezaei-Matehkolaei
ZJZahra Jahanshiri
Zahra Jahanshiri
MSMohammad‐Reza Shidfar
Mohammad‐Reza Shidfar
HMHossein Mirhendi
Hossein Mirhendi

22 March 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
SAShima Aboutalebian
Shima Aboutalebian
SMShahram Mahmoudi
Shahram Mahmoudi
ACArezoo Charsizadeh
Arezoo Charsizadeh
BNBahram Nikmanesh
Bahram Nikmanesh
MRMahnaz Hosseini Rizi
Mahnaz Hosseini Rizi
HMHossein Mirhendi
Hossein Mirhendi
Background: Multiple yeast species can cause human disease, involving superficial to deep‐seated infections. Treatment of these infections depends on the accurate identification of causative agents; however, reliable methods are not available in many laboratories, especially not in resource‐limited settings. Here, a new multiplex assay for rapid and low‐cost identification of pathogenic yeasts is described.Methods: A two‐step multiplex assay named YEAST PLEX that comprises of four tubes and identifies 17 clinically important common to rare yeasts was designed and evaluated. The set also provides PCR amplicon of unidentified species for direct sequencing. The specificity of YEAST PLEX was tested using 28 reference strains belonging to 17 species and 101 DNA samples of clinically important non‐target bacteria, parasites, and fungi as well as human genomic DNA. The method was further analyzed using 203 previously identified and 89 unknown clinical yeast isolates. Moreover, the method was tested for its ability to identify mixed yeast colonies by using 18 mixed suspensions of two or three species.Results: YEAST PLEX was able to identify all the target species without any non‐specific PCR products. When compared to PCR‐sequencing/MALDI‐TOF, the results of YEAST PLEX were in 100% agreement. Regarding the 89 unknown clinical isolates, random isolates were selected and subjected to PCR‐sequencing. The results of sequencing were in agreement with those of YEAST PLEX. Furthermore, this method was able to correctly identify all yeasts in mixed suspensions.Conclusion: YEAST PLEX is an accurate, low‐cost, and rapid method for identification of yeasts, with applicability, especially in developing countries.

14 September 2023 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
MEMahzad Erami
Mahzad Erami
SAShima Aboutalebian
Shima Aboutalebian
SHSeyed Jamal Hashemi Hezaveh
Seyed Jamal Hashemi Hezaveh
AMAmir Hassan Matini
Amir Hassan Matini
MMMansooreh Momen-Heravi
Mansooreh Momen-Heravi
HMHossein Mirhendi
Hossein Mirhendi
Invasive fungal rhinosinusitis (IFRS) is a life-threatening infection that can occur in immunocompromised patients, including those with COVID-19. Although Mucorales and Aspergillus species are the most common causes of IFRS, infections caused by other fungi such as Fusarium are rare. In this report, we present three cases of proven rhinosinusitis fusariosis that occurred during or after COVID-19 infection. The diagnosis was confirmed through microscopy, pathology, and culture, and species identification of the isolates was performed by DNA sequencing the entire ITS1-5.8 rRNA-ITS2 region and translation elongation factor 1-alpha (TEF-1α). Antifungal susceptibility testing was conducted according to CLSI guidelines. The causative agents were identified as Fusarium proliferatum, F. oxysporum + Aspergillus flavus, and F. solani/falciforme. Treatment involved the administration of antifungal medication and endoscopic sinus surgery to remove the affected mucosa, leading to the successful resolution of the infections. However, one patient experienced a recurrence of IFRS caused by A. flavus 15 months later. Early diagnosis and timely medical and surgical treatment are crucial in reducing mortality rates associated with invasive fusariosis. Additionally, the cautious use of corticosteroids in COVID-19 patients is highly recommended.